TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Meribel Pharma Höganäs AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
15,139
|
16,877
|
14,642 |
| Financial expenses |
396
|
772
|
733 |
| Earnings before taxes |
-3,499
|
-1,452
|
-2,078 |
| EBITDA |
-2,545
|
-186
|
-1,026 |
| Total assets |
16,090
|
16,068
|
10,794 |
| Current assets |
13,158
|
12,693
|
6,644 |
| Current liabilities |
4,158
|
14,334
|
10,082 |
| Equity capital |
11,933
|
1,734
|
713 |
| - share capital |
9
|
9
|
9 |
| Employees (average) |
89
|
91
|
103 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
74.2%
|
10.8%
|
6.6% |
| Turnover per employee |
170
|
185
|
142 |
| Profit as a percentage of turnover |
-23.1%
|
-8.6%
|
-14.2% |
| Return on assets (ROA) |
-19.3%
|
-4.2%
|
-12.5% |
| Current ratio |
316.5%
|
88.6%
|
65.9% |
| Return on equity (ROE) |
-29.3%
|
-83.7%
|
-291.4% |
| Change turnover |
-1,164
|
2,192
|
3,521 |
| Change turnover % |
-7%
|
15%
|
32% |
| Chg. No. of employees |
-2
|
-12
|
-3 |
| Chg. No. of employees % |
-2%
|
-12%
|
-3% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.